NEUROENDOCRINE PROSTATE CANCER
Clinical trials for NEUROENDOCRINE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for rare, aggressive prostate cancer
Disease control OngoingThis study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…
Matched conditions: NEUROENDOCRINE PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-phase trial tests an investigational drug called ABBV-706, alone or combined with other drugs, in about 288 adults with advanced solid tumors like small cell lung cancer, high-grade brain tumors, and neuroendocrine cancers. The main goals are to check safety, find the …
Matched conditions: NEUROENDOCRINE PROSTATE CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug cocktail targets tough prostate cancer
Disease control OngoingThis study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…
Matched conditions: NEUROENDOCRINE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Andrew J. Armstrong, MD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will tak…
Matched conditions: NEUROENDOCRINE PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC